Molecular Testing for Cutaneous Melanoma
To try to address the many controversies regarding molecular testing, the NCCN Guidelines for Cutaneous Melanoma now includes a lengthy section on the Principles of Molecular Testing. This covers molecular tests in development that are not yet recommended, and describes recommended tests, the contexts in which they should be employed, and how to use results to inform clinical management. 
Cutaneous Melanoma: Management of Melanoma Brain Metastases
Expert review of the data and presentation of different approaches to complex cases would help clinicians appreciate the range of clinical practice across NCCN Member Institutions, and highlight key considerations when presenting patients with options for treatment.
NCCN Guidelines® Insights - Melanoma: Cutaneous, Version 2.2021
These NCCN Guidelines Insights discuss the important changes to pathology and surgery recommendations, as well as additions to systemic therapy options for patients with advanced disease.
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Melanoma
Since immune checkpoint inhibitors and BRAF targeted therapies are now available, there are many patients with advanced melanoma who are surviving multiple lines of treatment, so the complexity of cases is increasing.
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Melanoma
Since immune checkpoint inhibitors and BRAF targeted therapies are now available, there are many patients with advanced melanoma who are surviving multiple lines of treatment, so the complexity of cases is increasing.
NCCN Guidelines® Insights - Uveal Melanoma, Version 1.2019

The NCCN Guidelines for Uveal Melanoma include recommendations for staging, treatment, and follow-up of patients diagnosed with uveal melanoma of the choroid or ciliary body.

Biomarker Testing for Immunotherapy

Recommendations and requirements for biomarker testing vary by the type of immune checkpoint inhibitor (ICI), specific tumor characteristics, and treatment setting.

Mutation Testing and Adjuvant Systemic Therapy in Cutaneous Melanoma

Several new adjuvant systemic therapy options for adjuvant treatment of stage III melanoma were added to the melanoma guidelines in v2018, such that there are now multiple adjuvant systemic therapy options in some settings.

Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Melanoma

Primary and Adjuvant Treatment for Stage III Disease

Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Melanoma

Primary and Adjuvant Treatment for Stage III Disease

Pages

Subscribe to RSS - Melanoma